Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.52 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.49 |
| ▸ | PTPRB | P23467 | 1/20 | 0.48 |
| ▸ | CDC25A | P30304 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | PTEN | P60484 | 1/20 | 0.48 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664152 | 0.84 | KEAP1 (0.59) | KEAP1PRMT6PPARDHPGDTSHR | |
| SCHEMBL12302785 | 0.83 | PRMT6 (0.59) | KEAP1PRMT6FFAR1PPARDKDM4E | |
| SCHEMBL10242910 | 0.81 | PRMT6 (0.53) | KEAP1PRMT6FFAR1KDM4EMEN1 | |
| SCHEMBL4137181 | 0.81 | PRMT6 (0.50) | KEAP1PRMT6KDM4EHPGD | |
| SCHEMBL1346211 | 0.81 | PRMT6 (0.59) | KEAP1PRMT6KDM4E | |
| SCHEMBL12303899 | 0.79 | PRMT6 (0.51) | KEAP1PRMT6KDM4EMEN1HPGD | |
| SCHEMBL29381971 | 0.79 | FFAR1 (0.69) | KEAP1FFAR1LIPGPTPRBCDC25A | |
| SCHEMBL7347912 | 0.79 | FFAR1 (0.69) | KEAP1FFAR1LIPGPTPRBCDC25A | |
| SCHEMBL10245034 | 0.78 | PRMT6 (0.64) | KEAP1PRMT6KDM4E | |
| SCHEMBL1347949 | 0.78 | PRMT6 (0.59) | KEAP1PRMT6FFAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20080255167-A1 | Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use | ASTEX THERAPEUTICS LTD. (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255167-A1 | Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use | ASTEX THERAPEUTICS LTD. (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255167-A1 | Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use | ASTEX THERAPEUTICS LTD. (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1951681-A1 | NOVEL 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058581-A1 | NOVEL 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058581-A1 | NOVEL 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | KEAP1 659/4885PRMT6 553/4885FFAR1 1823/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | KEAP1 1507/4885PRMT6 1140/4885FFAR1 2307/4885 |
| US-20080255167-A1 | Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use | PSEN2, PSEN1, MAPT | KEAP1 493/4885PRMT6 103/4885FFAR1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.